Correlation Between Merck and Anebulo Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Merck and Anebulo Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Merck and Anebulo Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Merck Company and Anebulo Pharmaceuticals, you can compare the effects of market volatilities on Merck and Anebulo Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Merck with a short position of Anebulo Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Merck and Anebulo Pharmaceuticals.
Diversification Opportunities for Merck and Anebulo Pharmaceuticals
0.21 | Correlation Coefficient |
Modest diversification
The 3 months correlation between Merck and Anebulo is 0.21. Overlapping area represents the amount of risk that can be diversified away by holding Merck Company and Anebulo Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Anebulo Pharmaceuticals and Merck is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Merck Company are associated (or correlated) with Anebulo Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Anebulo Pharmaceuticals has no effect on the direction of Merck i.e., Merck and Anebulo Pharmaceuticals go up and down completely randomly.
Pair Corralation between Merck and Anebulo Pharmaceuticals
Considering the 90-day investment horizon Merck Company is expected to under-perform the Anebulo Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Merck Company is 3.8 times less risky than Anebulo Pharmaceuticals. The stock trades about -0.07 of its potential returns per unit of risk. The Anebulo Pharmaceuticals is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest 164.00 in Anebulo Pharmaceuticals on December 28, 2024 and sell it today you would lose (28.00) from holding Anebulo Pharmaceuticals or give up 17.07% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Merck Company vs. Anebulo Pharmaceuticals
Performance |
Timeline |
Merck Company |
Anebulo Pharmaceuticals |
Merck and Anebulo Pharmaceuticals Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Merck and Anebulo Pharmaceuticals
The main advantage of trading using opposite Merck and Anebulo Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Merck position performs unexpectedly, Anebulo Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anebulo Pharmaceuticals will offset losses from the drop in Anebulo Pharmaceuticals' long position.Merck vs. Emergent Biosolutions | Merck vs. Bausch Health Companies | Merck vs. Neurocrine Biosciences | Merck vs. Teva Pharma Industries |
Anebulo Pharmaceuticals vs. Adagene | Anebulo Pharmaceuticals vs. Acrivon Therapeutics, Common | Anebulo Pharmaceuticals vs. AnaptysBio | Anebulo Pharmaceuticals vs. Mineralys Therapeutics, Common |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Complementary Tools
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |